Ontology highlight
ABSTRACT:
SUBMITTER: Lin JJ
PROVIDER: S-EPMC5659942 | biostudies-literature | 2017 Nov
REPOSITORIES: biostudies-literature
Lin Jessica J JJ Shaw Alice T AT
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20170814 11
ROS1 is a validated therapeutic target in NSCLC. In a phase I study, the multitargeted MET proto-oncogene, receptor tyrosine kinase/anaplastic lymphoma kinase/ROS1 inhibitor crizotinib demonstrated remarkable efficacy in ROS1-rearranged NSCLCs and consequently gained approval by the United States Food and Drug Administration and by the European Medicines Agency in 2016. However, similar to other oncogene-driven lung cancers, ROS1-rearranged lung cancers treated with crizotinib eventually acquire ...[more]